US-Europe Banking Bonuses Gap Is Narrowing
Ever since the global financial crisis, in an attempt to align pay to shareholder returns, banks have relied more heavily on restricted stock units when they're handing out bonuses. An analysis of 12 major banks found that the awards given out by US banks ended up being more valuable than those from their European counterparts in the 16 years since the aftermath of the Lehman collapse — but that gap is closing. Bloomberg's Jenny Surane reports. (Source: Bloomberg)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
CNBC
10 hours ago
- CNBC
Boeing trims projection for 20-year jet demand
Boeing expects global demand for air travel to increase by more than 40% by 2030, driving the need for thousands of new jetliners in the next few years, according to its 20-year demand forecast for commercial airliners released Sunday ahead of the Paris Airshow. The company expects demand for 43,600 new airliners through 2044. That is essentially the same as last year's edition, which projected demand for 43,975 new deliveries through 2043. European rival Airbus last week revised up its own 20-year commercial demand forecast by 2% to 43,420 jets, saying the air transport industry was expected to ride out current trade tensions. Boeing's delivery projection includes nearly 33,300 single-aisle airliners, just over 7,800 widebody jets, 955 factory-built freighters and 1,545 regional jets. Single-aisle jets include the 737 MAX and competitor Airbus's A320neo family and make up roughly four of every five deliveries now. While Boeing's deliveries projection is roughly the same, it pared down its 20-year forecast for passenger traffic growth from 4.7% in last year's outlook to 4.2% this year. Likewise, it lowered its global economic growth forecast from 2.6% to 2.3%, cargo traffic growth from 4.1% to 3.7% and fleet growth from 3.2% to 3.1%. Despite the lower projection for cargo traffic, Boeing Vice President of Commercial Marketing Darren Hulst told reporters in a briefing that trade volatility is not expected to significantly shift long-term demand. "I think we need to point back to the perspective that the last 20, 40, 60 years have given us in terms of the value of air cargo, and the fact that it's roughly a 4% growth market through all this time," he said. Since Covid-19, air travel demand has bounced back, but airplane production is only half or even less than what it was before the pandemic, resulting in a shortage of 1,500 to 2,000 airliners, he said. Both Airbus and Boeing have struggled to return aircraft production to pre-pandemic levels. Boeing has been dealing with production safety concerns following a 2024 mid-air blowout of a panel on a nearly new Alaska Airlines 737 Max. As a result, the U.S. Federal Aviation Administration capped 737 production at 38 airplanes a month. Boeing has significantly improved production quality in recent months, but the crash of an Air India Boeing 787-8 Dreamliner on Thursday put it back in crisis mode. CEO Kelly Ortberg cancelled his plans to attend the Paris Airshow in order to assist with the crash investigation. Global air travel is projected to increase by more than 40% by 2030, compared to the pre-pandemic high, according to the forecast. During the next 20 years, Boeing expects about 51% of demand for new aircraft to come from growth rather than replacing older airplanes. China and South/Southeast Asia, which includes India, are expected to account for half of that additional capacity, according to the outlook. North America and Eurasia account for more than half of projected deliveries for replacing older aircraft. China makes up an estimated 10% of Boeing's existing order backlog. The country paused taking delivery of new Boeing aircraft as China and the U.S. clashed over tariffs. However, deliveries are expected to resume this month, Ortberg said in May during an investors conference.
Yahoo
14 hours ago
- Yahoo
Litecoin Price Struggles Despite ETF Optimism as War Tensions Rattle Market
Litecoin LTC fell more than 4.3% over the past week, and is down more than 14% for the last 30-day period, with the latest sell-off coming as part of a wider risk asset sell-off. That sell-off came after Israel attacked Iran in a bid to put an end to its nuclear program and harm its missile capabilities, and Iran later retaliated with a salvo of missiles. The conflict has spooked global markets, reducing the total cryptocurrency market capitalization by more than $150 billion. LTC was severely affected by the sell-off. As the dust settled, Litecoin attempted a fragile rebound, climbing back above $86. But the recovery has stalled under mounting technical resistance. The $97.80 level, coinciding with the 23.6% Fibonacci retracement according to to CoinDesk Research's technical analysis data model, has proven difficult to breach. Momentum indicators like RSI at 43.46 and a flat MACD histogram show limited energy behind the move, suggesting a phase of consolidation. Volume tells a similar story. Litecoin's trading activity dropped 42% following the initial plunge, even as it briefly surged through the $85.90 resistance level during a high-volume spike late Friday. That breakout, however, was quickly met with profit-taking that brought it back down to $85. Looming in the background is hope for a spot litecoin ETF. Bloomberg ETF analysts Eric Balchunas and James Seyffart estimate a 90% chance of approval. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
